Earnings from pharmaceutical exports grew by nearly a quarter to $48.18 million in the first eight months of the current fiscal year.
The success of pharmaceutical companies in the global market, should come as no surprise, as locally owned companies have long supplied the bulk of the 97% of medicines sold in the country, which are made in Bangladesh.
While national demand is expected to grow healthily to over $3bn within the next decade, exports are an increasingly important factor for the industry. This can be seen by the sector’s ability to reach beyond markets in Asia, to a position where its competitive prices and high quality are helping it to sell medicines to 79 different countries including Brazil, Kenya and the UK.
A growing number of companies are backing the sector to create new jobs and generate vital foreign revenues, by investing in new plants and technology.
It is important that policymakers recognise and take action to help the industry overcome obstacles it faces as the sector clearly has potential for exports to take off much faster than at present.
The government can help by rectifying the delays which some businesses still face in getting clearances for exporting pharmaceutical products.
It should also strengthen the drug administration so that there is full and speedy access to testing laboratories to certify the products, and help increase export volumes.



